No, it was approved based on projected survival, and it’s an external device. The approval was actually based on PFS, the projected survival was ancillary to PFS. Again, endpoint was PFS, PFS is a surrogate or proxy measure for survival but it doesn’t always pan out. Manipulation and false projections based on proxies for survival is really the issue you are trying to articulate, but NWBO had a long trial to measure ACTUAL survival. So, assuming DCVax-L is approved, unlike Optune, it will have been approved based upon ACTUAL survival. Optune was not approved based on that measure.
Market Data 
Markets 
AI
